Till sidans topp

Sidansvarig: Webbredaktion
Sidan uppdaterades: 2012-09-11 15:12

Tipsa en vän
Utskriftsversion

Coping with the financier… - Göteborgs universitet Till startsida
Webbkarta
Till innehåll Läs mer om hur kakor används på gu.se

Coping with the financiers: attracting venture capital investors and end-users in the biomaterials industry

Artikel i vetenskaplig tidskrift
Författare Alexander Styhre
Publicerad i Technology Analysis & Strategic Management
Volym 26
Nummer/häfte 7
Sidor 797-809
ISSN 0953-7325
Publiceringsår 2014
Publicerad vid Företagsekonomiska institutionen, Management & Organisation
Sidor 797-809
Språk en
Länkar dx.doi.org/10.1080/09537325.2014.90...
Ämnesord venture capital, biomaterials, medical devices, university spin-outs, health care innovations, UNIVERSITY-RESEARCH CENTERS, ENTREPRENEURIAL UNIVERSITY, BUSINESS MODEL, INNOVATION, PATENTS, FIRMS, Management, Multidisciplinary Sciences, ONOMIC ENGINE, P1
Ämneskategorier Juridik

Sammanfattning

A substantial amount of research has been committed to exploring how university-based research can be transferred to industry and be commercialised. This literature emphasises the substantial institutional, cultural and financial barriers to what has been referred to as academic entrepreneurship. At the same time, and most noteworthy in the USA, university patenting has grown remarkably since the mid-1960s; today (2014), much of the basic life science research conducted by universities is being transformed into health care innovations. This paper reports on a case study of the biomaterials and medical device industry in Sweden and emphasises that, while capital funding is a key challenge for university spin-outs, an additional and less widely recognised concern facing these companies is how to make the public sector health care organisations, primarily, actually buy the products developed. The study suggests that perhaps too much emphasis is being put on 'upstream activities', including the early stage support provided by incubators and state agencies that provide seed-money funding, while more mature biomaterials and medical device companies are suffering from both a lack of unified regulatory frameworks and policies governing the procurement of new health care innovations.

Sidansvarig: Webbredaktion|Sidan uppdaterades: 2012-09-11
Dela:

På Göteborgs universitet använder vi kakor (cookies) för att webbplatsen ska fungera på ett bra sätt för dig. Genom att surfa vidare godkänner du att vi använder kakor.  Vad är kakor?